By the mid-1970s the autoimmune origin of myasthenia gravis had been well established. Once this feat had been accomplished, it also became apparent that myasthenic disorders occurring in a genetic or congenital setting had a different etiology. As a result, a number of distinct myasthenic syndromes have been recognized and investigated by electrophysiological and ultrastructural methods. The newly recognized disorders are conditioned by divergent causes, such as a failure of acetylcholine resynthesis or packaging, absence of acetylcholinesterase from the neuromuscular junction, abnormal gating properties of the acetylcholine receptor-associated ion channel, or an abnormality in the regulation of the density of acetylcholine receptor molecules in the postsynaptic membrane. These genetic defects either impair neuromuscular transmission directly or result in secondary derangements that eventually compromise the safety margin of neuromuscular transmission. (J Child Neurol 1988;3:233-246).
Get full access to this article
View all access options for this article.
References
1.
Salpeter MM (ed): The Vertebrate Neuromuscular Junction. New York, Alan R Liss Inc, 1987.
2.
Magleby KL: Neuromuscular transmission, in Engel AG , Banker BQ (eds): Myology. New York, McGraw-Hill, 1986, pp 393-418.
3.
Engel AG: The neuromuscular junction, in Engel AG , Banker BQ (eds): Myology. New York, McGraw-Hill, 1986, pp 209-254.
4.
Greer M., Schotland M.: Myasthenia gravis in the newborn. Pediatrics1960;26:101-108.
5.
Conomy JP, Levisohn M., Fanaroff A.: Familial infantile myasthenia gravis: A cause of sudden death in young children . J Pediatr1975;87:428-429.
Gieron MA, Korthals JK: Familial infantile myasthenia gravis: Report of three cases with follow-up until adult life. Arch Neurol1985;42:143-144.
8.
Engel AG, Lambert EH, Mulder DM, Gomez MR: Recently recognized congenital myasthenic syndromes: (A) End-plate acetylcholine (ACh) esterase deficiency. (B) Putative abnormality of the ACh induced ion channel. (C) Putative defect of ACh resynthesis or mobilization-clinical features, ultrastructure and cytochemistry. Ann NY Acad Sci1981;377:614-639.
9.
Engel AG: Myasthenic syndromes, in Engel AG, Banker BQ (eds): Myology. New York, McGraw-Hill , 1986, pp 1955-1990.
Hart Z., Sahashi K., Lambert EH, et al: A congenital, familial, myasthenic syndrome caused by a presynaptic defect of transmitter resynthesis or mobilization, abstract. Neurology1979;29: 559.
12.
Mora M., Lambert EH, Engel AG: Synaptic vesicle abnormality in familial infantile mvasthenia. Neurology1987;37:206-214.
13.
Elmqvist D. , Quastel DMJ: Presynaptic action of hemicholinium at the neuromuscular junction. J Physiol (Lond)1965;177:463-482.
14.
Jones SF, Kwanbunbumpen S.: The effects of nerve stimulation and hemicholinium on synaptic vesicles at the mammalian neuromuscular junction. J Physiol (Lond)1970;207:31-50.
15.
Jones SF, Kwanbunbumpen S.: Some effects of nerve stimulation and hemicholinium on quantal transmitter release at the mammalian neuromuscular junction. J Physiol (Lond)1970;207: 51-61.
16.
Wolters CMJ , Leeuwin RS, Van Wijngaarden KV: The effect of prednisolone on the rat phrenic nerve-diaphragm preparation treated with hemicholinium . Eur J Pharmacol1974;29:165-167.
17.
Anderson DC , King SC, Parsons SM: Pharmacological characterization of the acetylcholine transport system in purefied Torpedo electric organ synaptic vesicles. Mol Pharmacol1983; 24:48-54.
18.
Harlos P., Lee DA, Stadler H.: Characterization of a Mg2+-ATPase and a proton pump in cholinergic synaptic vesicles from the electric organ of Torpedo marmorata. Eur J Biochem1984;144:441-446.
19.
Whittaker VB : The structure and function of cholinergic synaptic vesicles. Biochem Soc Trans1984;12:561-578.
20.
Wagner JA, Carlson SC, Kelly RB: Chemical and physical characterization of cholinergic synaptic vesicles . Biochemistry1978;17:1199-1206.
21.
Engel AG, Lambert EH, Gomez MR: A new myasthenic syndrome with end-plate acetylcholinesterase deficiency, small nerve terminals and reduced acetylcholine release. Ann Neurol1977;1:315-330.
22.
Engel AG, Lambert EH, Santa T.: Study of long-term anticholinesterase therapy: Effects on neuromuscular transmission and on motor end-plate fine structure. Neurology1973;23:1273-1281.
23.
Laskowski MB , Olson WH, Dettbarn WD: Ultrastructural changes at the motor end-plate produced by an irreversible cholinesterase inhibitor . Exp Neurol1975;47:290-306.
24.
Salpeter MM , Kasprzak H., Feng H., Fertuck H.: End-plates after esterase inactivation in vivo: Correlation between esterase concentration, functional response and fine structure. J Neurocytol1979;8:95-115.
25.
Engel AG, Lambert EH, Mulder DM, et al: A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion channel. Ann Neurol1982;11:553-569.
26.
Oosterhuis Hjgh, Newsom-Davis J., Wokke JHJ, et al: The slow channel syndrome: Two new cases. Brain1987 ;110:1061-1079.
27.
DelCastillo J., Katz B.: Localization of active spots within the neuromuscular junction of the frog. J Physiol (Lond)1956;132: 160-649.
28.
Vigny M., Bon S., Massoulie J., Gisiger V.: The subunit structure of mammalian acetylcholinesterase: Catalytic subunits, dissociating effects of proteolysis and disulphide reduction on the polymeric forms. J Neurochem1979;33:559-565.
29.
Takeuchi N. : Effects of calcium on the conductance change of the end-plate membrane during the action of the transmitter. J Physiol (Lond)1963;167:141-155.
30.
Evans RH: The entry of labelled calcium into the innervated region of the mouse diaphragm muscle. J Physiol (Lond)1974 ; 240:517-533.
31.
Miledi R., Parker I., Schalow G.: Transmitter induced calcium entry across the postsynaptic membrane at frog end-plates measured using arsenazo III. J Physiol (Lond)1980;300:197-212.
32.
Ebashi S., Sugita H.: The role of calcium in physiological and pathological processes of skeletal muscle. Excerpta Medica ICS1979;455:73-84.
33.
Jackson MJ, Jones DA, Edwards RHT: Experimental skeletal muscle damage: The role of calcium activated degenerative processes. Eur J Clin Invest1984;14:369-375.
34.
Leonard JP, Salpeter MM: Calcium-mediated myopathy at neuromuscular junctions of normal and dystrophic muscle. Exp Neurol1982;46:121-138.
35.
Gardner JM, Fambrough DM: Acetylcholine receptor degradation measured by density labeling: Effects of cholinergic ligands and evidence against recycling. Cell1979;16:661-674.
36.
Schuetze SM : Developmental regulation of acetylcholine receptors . Ann Rev Neurosci1987;10:403-457.
37.
Mishina M., Takai T., Imoto K., et al: Molecular distinction between fetal and adult forms of muscle acetylcholine receptor. Nature1986;321:406-411.
38.
Witzemann V. , Barg B., Nishikawa Y., et al: Differential regulation of muscle acetylcholine receptor gamma and epsilonsubunit mRNAs. FEBS Lett1987;223:104-112.
39.
Gu Y., Hall ZW: Immunological evidence for a change in subunits of the acetylcholine receptor in developing and denervated rat muscle. Neuron1988; 1:117-125.
40.
Vincent A., Cull-Candy SG, Newsom-Davis J., et al: Congenital myasthenia: End-plate acetylcholine receptors and electrophysiology in five cases. Muscle Nerve1981;4:306-318.
41.
Lecky BRF , Morgan-Hughes JA, Murray NMF , et al: Congenital myasthenia: Further evidence of disease heterogeneity . Muscle Nerve1986 ;9:233-242.
42.
Smit SME , Jennekens FGI , Veldman H., Barth PG: Paucity of secondary synaptic clefts in a case of congenital myasthenia with multiple contractures: Ultrastructural morphology of a developmental disorder . J Neurol Neurosurg Psychiatry1984;47: 1091-1097.
43.
Smit LME , Hageman G., Veldman H., et al: A myasthenic syndrome with congenital paucity of secondary synaptic clefts: CPSC syndrome. Muscle Nerve1988;11:337-348.
44.
Morgan-Hughes JA, Lecky BRF, Landon DN, Murray NMF: Alterations in the number and affinity of junctional acetylcholine receptors in a myopathy with tubular aggregates: A newly recognized receptor defect. Brain1981;4:279-295.
45.
Albers JW, Faulkner JA, Dorovini-Zis K., et al: Abnormal neuromuscular transmission in an infantile myasthenic syndrome. Ann Neurol1984;16:28-34.
